Table 3.

Representative NHLBI PACT cell therapy products: from key scientific rationale in the literature to clinical application in human cellular therapy

Cell product	Clinical rationale	Scientific basis citations	Clinical application citations
LMP1–and LMP2‐specific cytotoxic T‐lymphocytes	Epstein‐Barr virus—associated lymphoma	31	31
Tri‐virus—specific cytotoxic T‐lymphocytes (nucleofected with plasmids)	Prevention and treatment of cytomegalovirus (CMV), EBV, and adenovirus post hematopoietic stem cell transplantation (HSCT)	32, 33	33–39
Bone marrow—derived mononuclear cells	Traumatic brain injury	40	41
Bone marrow—derived mononuclear cells	Acute myocardial infarction	–	42, 43
Expanded T‐regulatory cells	Prevention of GVHD	44–48	48
Autologous mature apoptotic dendritic cells with HIV‐1	Improving host immune control of residual host immune HIV infection during highly active antiretroviral therapy (HAART)	49	50
Allogeneic haploidentical natural killer cells	Gain durable remission/HSCT preparative regimen	51	52